Potentiation of Glycine-Gated NR1/NR3A NMDA Receptors Relieves Ca-Dependent Outward Rectification.
Glycine has diverse functions within the mammalian central nervous system. It inhibits postsynaptic neurons via strychnine-sensitive glycine receptors (GlyRs) and enhances neuronal excitation through co-activation of N-methyl-D-aspartate (NMDA) receptors. Classical Ca(2+)-permeable NMDA receptors are composed of glycine-binding NR1 and glutamate-binding NR2 subunits, and hence require both glutamate and glycine for efficient activation. In contrast, recombinant receptors composed of NR1 and the glycine binding NR3A and/or NR3B subunits lack glutamate binding sites and can be activated by glycine alone. Therefore these receptors are also named "excitatory glycine receptors". Co-application of antagonists of the NR1 glycine-binding site or of the divalent cation Zn(2+) markedly enhances the glycine responses of these receptors. To gain further insight into the properties of these glycine-gated NMDA receptors, we investigated their current-voltage (I-V) dependence. Whole-cell current-voltage relations of glycine currents recorded from NR1/NR3B and NR1/NR3A/NR3B expressing oocytes were found to be linear under our recording conditions. In contrast, NR1/NR3A receptors displayed a strong outwardly rectifying I-V relation. Interestingly, the voltage-dependent inward current block was abolished in the presence of NR1 antagonists, Zn(2+) or a combination of both. Further analysis revealed that Ca(2+) (1.8 mM) present in our recording solutions was responsible for the voltage-dependent inhibition of ion flux through NR1/NR3A receptors. Since physiological concentrations of the divalent cation Mg(2+) did not affect the I-V dependence, our data suggest that relief of the voltage-dependent Ca(2+) block of NR1/NR3A receptors by Zn(2+) may be important for the regulation of excitatory glycinergic transmission, according to the Mg(2+)-block of conventional NR1/NR2 NMDA receptors.
Madry
Christian
C
Department of Neurochemistry, Max-Planck Institute for Brain Research Frankfurt am Main, Germany.
Betz
Heinrich
H
Geiger
Jörg R P
JR
Laube
Bodo
B
J Neurosci. 2009 Feb 25;29(8):2371-83
19244513
J Biol Chem. 2005 Aug 19;280(33):29708-16
15970596
J Neurosci. 1995 Oct;15(10):6509-20
7472413
Neuron. 2000 Oct;28(1):165-81
11086992
Nat Rev Neurosci. 2005 Jun;6(6):449-62
15891778
Nature. 2002 Feb 14;415(6873):793-8
11823786
J Neurosci. 2006 Apr 26;26(17):4559-66
16641235
Neuron. 1997 Mar;18(3):493-503
9115742
Curr Opin Neurobiol. 2001 Jun;11(3):327-35
11399431
Mol Pharmacol. 2007 Dec;72(6):1535-44
17878266
Neuron. 1995 Jul;15(1):193-204
7619522
Neuropharmacology. 2004 Dec;47(7):994-1007
15555634
Biochem Biophys Res Commun. 2007 Mar 2;354(1):102-8
17214961
Proc Natl Acad Sci U S A. 1986 Sep;83(18):7104-8
3529096
Neuron. 2006 Nov 22;52(4):679-90
17114051
J Pharmacol Exp Ther. 2009 Dec;331(3):975-84
19726695
Pharmacol Rev. 1999 Mar;51(1):7-61
10049997
J Neurosci. 2006 Dec 20;26(51):13156-66
17182766
J Neurochem. 2006 Jun;97(6):1600-10
16805771
Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12563-8
18711142
J Physiol. 1995 Mar 15;483 ( Pt 3):613-9
7776247
J Biol Chem. 2008 Jan 4;283(1):37-46
17959602
J Neurosci. 2002 Dec 1;22(23):10209-16
12451122
Neuron. 1994 Jun;12(6):1291-300
8011339
Nature. 2006 Mar 23;440(7083):456-62
16554805
Nature. 2005 Nov 10;438(7065):185-92
16281028
J Neurophysiol. 2008 Jan;99(1):122-32
18003876
J Neurosci. 2001 Dec 1;21(23):RC185
11717388
Science. 1998 Jun 5;280(5369):1596-9
9616121
Neuron. 1996 Aug;17(2):343-52
8780657
Neuron. 2005 Mar 3;45(5):727-39
15748848
J Neurosci. 1998 Apr 15;18(8):2954-61
9526012
Nature. 1987 Feb 5-11;325(6104):529-31
2433595
Mol Pharmacol. 2007 Jan;71(1):112-22
17047094
Mol Pharmacol. 1998 May;53(5):933-41
9584221
Hear Res. 2000 Mar;141(1-2):117-28
10713500
Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14163-8
18779583
Hear Res. 2002 May;167(1-2):122-35
12117536